Compare Citius Pharmaceuticals Inc (CTXR) vs Nano Dimension Ltd - ADR (NNDM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Nano Dimension Ltd - ADR — how do they compare? Citius Pharmaceuticals Inc trades at $0.54 (market cap $14.64M), while Nano Dimension Ltd - ADR trades at $1.49 (market cap $314.71M). The key difference: Nano Dimension Ltd - ADR is far larger — about 21.5× Citius Pharmaceuticals Inc's market cap, and Nano Dimension Ltd - ADR is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | NNDM | |
|---|---|---|
Market Cap | $14.64M | $314.71M |
Sector | Health | Technology |
52-Week High | $1.82 | $2.14 |
52-Week Low | $0.53 | $1.21 |
Enterprise Value | $10.86M | -$94.63M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
Nano Dimension (NNDM) trades at $1.48, down 1.33% with a bearish technical signal. The company reported Q1 2026 revenue of $102.44M but a net loss of -$293.30M, reflecting a -286.72% margin. Cash burn remains high at -$101.28M from operations. Recent news highlights board disputes with shareholder Murchinson and a proposed merger with Infinite Epigenetics, creating uncertainty.
The outlook is challenged by persistent losses and negative cash flow, though the P/B of 0.64 suggests undervaluation. Risks include execution on strategic plans and shareholder activism. Analyst sentiment is cautious given the lack of profitability and ongoing corporate governance issues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Nano Dimension Ltd - ADR
Nano Dimension Ltd is engaged in research and development of a three-dimensional printer that prints electronic circuit boards, also known as printed circuit boards, and ink materials and products based on nanotechnology. Its products consist of two main product lines - Dragonfly 2020 3D printer and proprietary ink products. The company's Dragonfly 2020 3D printer currently in development uses proprietary ink and integrated software to quickly create fully functioning PCB prototypes. Geographically, it generates maximum revenue from the USA followed by the Asia Pacific and Europe and Israel. It serves the Commercial, Research and Printing services industries.
Read more on NNDM →
